Skip to content
October 04, 2022

Equity.Guru

Investment information for the new generation

MDP.T

Medexus Pharmaceuticals (MDP.T), is a Canadian-based specialty pharma firm focused on bringing already approved drugs from different regulatory jurisdictions into the Canadian and American market. Medexus has a diverse…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs…
Specialty pharma companies, like Medexus Pharmaceuticals (MDP.T), have an advantage over tradition pharmaceutical drug developers as they provide pre-approved products and typically don’t need to go through the FDA…
In today’s rant, Chris talks about the recent news regarding an FDA request for further information on Medexus’ Treosulfan application. The market reacted wildly to the news, causing a…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) provided an update on the Treosulfan NDA resubmission and provided a business update. On September 16th 2022, Medexus was informed by Medac, licensor…
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost….
In today’s episode, Equity.Guru founder, Chris Parry, talks with Ken d’Entremont, CEO and director of Medexus Pharmaceuticals, and asks about the company’s recent strong financials, the possible inclusion of…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company whose stock is on fire! The stock rallied 34% from its opening price to its highs last week. And it has…
Equity.Guru founder, Chris Parry, discusses Medexus Pharmaceuticals (MDP.T) and the positive portfolio potential the rapidly growing, revenue generating specialty pharma firm presents to public market investors. Enjoy!…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…